NY Yankee GM Spreads the Word About Prostate Cancer to African-American Men

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK--Baseball-Hall-of-Famer Bob Watson remembered feeling "on top of the world" in October, 1993, after being named the first African-American general manager of a major league ball club (the Houston Astros), but the very next year, at the age of 47, he was feeling "angry and afraid" after learning he had prostate cancer.

NEW YORK--Baseball-Hall-of-Famer Bob Watson remembered feeling"on top of the world" in October, 1993, after beingnamed the first African-American general manager of a major leagueball club (the Houston Astros), but the very next year, at theage of 47, he was feeling "angry and afraid" after learninghe had prostate cancer.

Mr. Watson, who is now the general manager of the New York Yankees,wants to get the message out--in particular to African-Americanswhose risk of developing prostate cancer is 37% higher than thatof white men--that all men should have an annual digital rectalexamination and a PSA test starting at age 50, and high-risk men(African-Americans and any man with a family history of prostatecancer) should begin testing at age 40.

"I believe the PSA test saved my life," he said at acombined American Cancer Society/Cancer Research Institute mediabriefing.

His PSA level of 5.8 set off a chain of events, including ultrasoundand biopsy, that showed "one of the most aggressive formsof prostate cancer," Mr. Watson said, but fortunately itwas still enclosed in the gland. His surgery was successful, andhe has been an outspoken patient activist ever since.

Mr. Watson pointed out that in 1996 some 40,000 American men willdie of prostate cancer, "more people than can fit in FenwayPark," the Boston stadium that seats 36,500.

A Prostate Cancer Day is planned for Yankee Stadium, he said,and, partly as a symbolic gesture to encourage older men to betested, all major league players will have a PSA test as partof their annual spring training physical.

SIDEBAR

Man-to-Man Promotes Awareness Among African-American Men

The American Cancer Society's new "Man-to-Man" programwill be using support groups to promote prostate cancer awarenessin the general population, but particularly among those who areat high-risk, especially in the African-American community.

"Man-to-Man," which is now on the Internet and can bereached at htp:--www.cancer.org, seeks to take the traditionalsupport group program, with its focus on group meetings, to anotherlevel: to reach patients in their own environment, preferablyat home, at the time the diagnosis is made.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content